Schizoaffective Disorders Completed Phase 3 Trials for Olanzapine (DB00334)

Also known as: Schizoaffective disorder / Schizophrenia schizoaffective / Schizoaffective psychosis / Schizo-affective type schizophrenia

IndicationStatusPhase
DBCOND0033299 (Schizoaffective Disorders)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00401973Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With OlanzapinePrevention
NCT00212784Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)Treatment
NCT00088465Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective DisorderTreatment
NCT00212771Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25520)(P05846)Treatment
NCT00797277Intramuscular (IM) Olanzapine Versus IM Haloperidol Plus Lorazepam for Acute Agitation in SchizophreniaTreatment